Toll Free: 1-888-928-9744

P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 52 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Review, H1 2016', provides in depth analysis on P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted pipeline therapeutics. 

The report provides comprehensive information on the P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P)
- The report reviews P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted therapeutics and enlists all their major and minor projects 
- The report assesses P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) Overview 7 Therapeutics Development 8 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Products under Development by Stage of Development 8 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Products under Development by Therapy Area 9 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Products under Development by Indication 10 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Products under Development by Companies 13 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Companies Involved in Therapeutics Development 21 Momenta Pharmaceuticals, Inc. 21 Pfizer Inc. 22 Selexys Pharmaceuticals Corporation 23 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Drug Profiles 24 GM-0111 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 necuparanib - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 pentosan polysulfate sodium - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 rivipansel sodium - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 SelG-1 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecules to Inhibit P-Selectin, L-Selectin and PMN Proteases for Oncology - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Dormant Projects 38 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Discontinued Products 40 P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Featured News & Press Releases 41 Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO 41 May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting 41 Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 42 Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 43 Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel 43 Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology 44 Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel 44 Jun 23, 2015: Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease 45 Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer 46 May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting 47 Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015 47 Mar 03, 2015: GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease 48 Dec 09, 2014: GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist Rivipansel at 56th ASH Annual Meeting 49 Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer 49 Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 21 Pipeline by Pfizer Inc., H1 2016 22 Pipeline by Selexys Pharmaceuticals Corporation, H1 2016 23 Dormant Projects, H1 2016 38 Dormant Projects (Contd..1), H1 2016 39 Discontinued Products, H1 2016 40


List of Figures
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Actions, H1 2016 16 Number of Products by Routes of Administration, H1 2016 17 Number of Products by Stage and Routes of Administration, H1 2016 17 Number of Products by Molecule Types, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 19

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growi

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify